The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- Researchers Explore Health-Promoting Behaviors of African American and Black Immigrant Men.
- New Technology Promises to Revolutionize Valvular Heart Disease Care.
- DNA test says it can predict opioid addiction risk. Skeptics aren’t so sure.
- Transfer Scholars Initiative prepares N.J. community college students to thrive at selective four-year schools.
- Scientists May Have Discovered Reason for Long COVID Brain Fog—Here’s Why It Matters.